Skip to content

US · MGRX · MEDICAL - HEALTHCARE INFORMATION SERVICES

Mangoceuticals, Inc. (MGRX) intrinsic value and stock valuation

$0.12as of 2026-11-21 · Mkt cap 7.22M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mangoceuticals, Inc. DCF and intrinsic value

InvestorsCraft values MGRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MGRX’s statements →

Mangoceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Dallas, TX 75248 mangoceuticals.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$460K
20212025
Net income
-$-20.64M
20212025
Free cash flow
-$-5.85M
20212025
Total equity
$15.2M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$460K$620K$730K$10K$0.00
Operating income-$-19.15M-$-7.97M-$-9.22M-$-1.99M-$-20K
Net income-$-20.64M-$-8.71M-$-9.21M-$-2M-$-20K
EPSd-$-2.05M-$-4.4M-$-8.61M-$-1.74M-$-20K
Operating cash flow-$-5.85M-$-4.86M-$-7M-$-1.35M-$-20K
Capital expenditure-$0.00$0.00-$0.00-$-40K$0.00
Free cash flow-$-5.85M-$-4.86M-$-7M-$-1.39M-$-20K
Total assets$16.1M$15.4M$1.05M$1M$20K
Total debt$310K$210K$130K$350K$40K
Net debt-$-1.18M$160K-$-610K-$-330K$20K
Total equity$15.2M$14M$770K$610K-$-20K
Cash and short-term investments$1.49M$60K$740K$680K$20K
Income statement
20252024202320222021
Revenue$460K$620K$730K$10K$0.00
Cost of revenue$210K$240K$300K$0.00$0.00
Gross profit$250K$380K$430K$0.00$0.00
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$16.7M$7.9M$5.42M$2M$20K
Other expenses$2.68M$450K$4.23M$0.00$0.00
Operating expenses$19.4M$8.35M$9.65M$2M$20K
Cost and expenses$19.6M$8.59M$9.95M$2M$20K
Interest income$0.00$0.00$10K$0.00$0.00
Interest expense$100K$10K$0.00$10K$0.00
Depreciation and amortization$1.72M$720K$20K$0.00$0.00
Ebitda-$-18.82M-$-7.96M-$-8.09M-$-1.99M-$-20K
Operating income-$-19.15M-$-7.97M-$-9.22M-$-1.99M-$-20K
Total other income/expenses, net-$-1.49M-$-730K$10K-$-10K-$0.00
Income before tax-$-20.64M-$-8.71M-$-9.21M-$-2M-$-20K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-20.64M-$-8.71M-$-9.21M-$-2M-$-20K
Weighted average shares outstanding$10.1M$1.98M$1.07M$1.15M$1M
Weighted average diluted shares outstanding$10.1M$1.98M$1.07M$1.15M$1M
Balance sheet
20252024202320222021
Cash and short-term investments$1.49M$60K$740K$680K$20K
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$20K$0.00$0.00
Total current assets$1.55M$80K$820K$690K$20K
Property, plant and equipment, net$310K$60K$220K$290K$0.00
Goodwill and intangible assets$14.2M$15.2M$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$14.5M$15.3M$230K$310K$0.00
Total assets$16.1M$15.4M$1.05M$1M$20K
Accounts payable$420K$840K$140K$30K$0.00
Short-term debt$310K$210K$60K$220K$40K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$890K$1.43M$210K$260K$40K
Long-term debt$0.00$0.00$60K$130K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$60K$130K$0.00
Capital lease obligations$310K$60K$130K$190K$0.00
Total liabilities$890K$1.43M$280K$390K$40K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-40.65M-$-20.81M-$-11.23M-$-2.02M-$-20K
Accumulated other comprehensive income (loss)-$0.00-$-10K$0.00$0.00$0.00
Total equity$15.2M$14M$770K$610K-$-20K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$310K$210K$130K$350K$40K
Net debt-$-1.18M$160K-$-610K-$-330K$20K
Cash flow statement
20252024202320222021
Net income-$-20.64M-$-8.71M-$-9.21M-$-2M-$-20K
Depreciation and amortization$1.12M$730K$20K$0.00$0.00
Stock-based compensation$1.17M$250K$620K$230K$0.00
Change in working capital$970K$660K$40K$20K$0.00
Accounts receivable-$-20K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$60K$700K$110K$30K$0.00
Net cash provided by operating activities-$-5.85M-$-4.86M-$-7M-$-1.35M-$-20K
Investments in property, plant and equipment$0.00$0.00-$0.00-$-40K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$70K-$0.00-$-40K$0.00
Common stock issued$5.65M$1.33M$6.2M$2M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-800K$0.00$0.00$0.00
Net cash used for financing activities$7.27M$4.13M$7.06M$2.05M$40K
Net change in cash$1.43M-$-680K$60K$660K$20K
Cash at end of period$1.49M$60K$740K$680K$20K
Operating cash flow-$-5.85M-$-4.86M-$-7M-$-1.35M-$-20K
Capital expenditure-$0.00$0.00-$0.00-$-40K$0.00
Free cash flow-$-5.85M-$-4.86M-$-7M-$-1.39M-$-20K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mangoceuticals, Inc.

        Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.

        CEO
        Jacob D. Cohen
        Employees
        3
        Beta
        2.28

        Explore

        Frequently asked questions

        What is the intrinsic value of Mangoceuticals, Inc. (MGRX)?

        InvestorsCraft does not currently publish an intrinsic value for MGRX. How the IC value is calculated.

        Is MGRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for MGRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.